News Waldemar Heiduk

(1 - 4 von 5
)

BioCryst Announces Approval of ORLADEYO (berotralstat) ...Wallstreet Online

www.wallstreet-online.de
— ... once-daily prophylactic therapy last year,” said Waldemar Heiduk, chief executive officer of BioCryst Pharma Deutschland GmbH. › nachricht ›

2 More Countries Approve Orladeyo for Preventing HAE ...Angioedema News

angioedemanews.com
— ... many patients in Europe since we received European Commission approval,” said Waldemar Heiduk, CEO of BioCryst Pharma Deutschland GmbH. › ne...

BioCryst Stock: A Prudent Diversification (NASDAQ:BCRX)havannews.com › Stock Market

havannews.com
· Commenting on the recent approval, the CEO of BioCryst Pharma Deutschland GmbH (Waldemar Heiduk) noted: We have made significant progress in ...
+1